Ventana Medical’s HPV Claims Probed By FDA In Vitro Diagnostic Office
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical contends that its Inform HPV in-situ hybridization (ISH) probes qualify as analyte-specific reagents and do not require premarket notification, despite FDA's assertions to the contrary